Raymond James Downgrades Neogenomics (NEO) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts NEO Hot Sheet
Price: $17.01 +1.07%
Rating Summary:
15 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Rating Summary:
15 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Join SI Premium – FREE
Raymond James analyst Andrew Cooper downgraded Neogenomics (NASDAQ: NEO) from Outperform to Market Perform.
For an analyst ratings summary and ratings history on Neogenomics click here. For more ratings news on Neogenomics click here.
Shares of Neogenomics closed at $54.34 yesterday.
You May Also Be Interested In
- William Blair Downgrades Fidelity National Information Services (FIS) to Market Perform
- Barclays Downgrades Driven Brands (DRVN) to Underweight
- Citi Downgrades Camping World Holdings (CWH) to Neutral
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
